Back to Journals » Core Evidence » Volume 8

Lixivaptan – an evidence-based review of its clinical potential in the treatment of hyponatremia

Authors Bowman BT, Rosner MH

Received 13 May 2013

Accepted for publication 10 June 2013

Published 11 July 2013 Volume 2013:8 Pages 47—56

DOI https://doi.org/10.2147/CE.S36744

Checked for plagiarism Yes

Review by Single-blind

Peer reviewer comments 3


Brendan T Bowman, Mitchell H Rosner

Division of Nephrology, University of Virginia Health System, Charlottesville, VA, USA

Abstract: Hyponatremia is the most common electrolyte abnormality seen in clinical practice. Most cases of euvolemic or hypervolemic hyponatremia involve arginine vasopressin (AVP). AVP leads to a concentrated urine and negative free water clearance. Given this primary role of AVP, antagonizing its effect through blockade of its receptor in the distal tubule is an attractive therapeutic target. Lixivaptan is a newer, non-peptide, vasopressin type 2 receptor antagonist. Recent studies have demonstrated efficacy. This review summarizes the clinical pharmacology and data for this new agent.

Keywords: vasopressin, hyponatremia, heart failure, lixivaptan, therapy, outcomes

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF]  View Full Text [HTML][Machine readable]